CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to bind serum albumin so it stays active far longer than natural GHRH. It comes up constantly in growth-hormone-support conversations, often paired with ipamorelin. The published evidence is smaller and older than most people assume, and it includes a safety episode worth knowing about before anyone forms an opinion on it.

What it is

Natural GHRH signals the pituitary gland to release growth hormone, but it breaks down within minutes. CJC-1295 was designed with a modification — a Drug Affinity Complex (DAC) that binds covalently to albumin in the blood — extending its half-life from minutes to roughly 6–8 days, allowing infrequent dosing while still stimulating the same GHRH receptor pathway. A version without the DAC modification (sometimes called “CJC-1295 without DAC,” structurally closer to a peptide called Mod GRF 1-29) has a much shorter half-life and is a functionally different product despite the shared name.

What the evidence shows — and where the gaps are

• The core human data is a single 2006 trial program. Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism, ran two randomized, double-blind, placebo-controlled dose-escalation trials in healthy adults. A single dose raised mean growth hormone 2- to 10-fold for about 6 days and IGF-1 1.5- to 3-fold for 9–11 days — confirming the mechanism works pharmacologically, in a small, short-duration, healthy-volunteer setting.
• No published trial has measured the outcomes it’s actually discussed for. Muscle strength, body composition, exercise capacity, sleep quality, cognitive function, or injury recovery have not been studied for CJC-1295 in a published human trial. The evidence supports “it raises GH and IGF-1 for about a week”; it does not support any downstream claim built on top of that.
• A related trial was halted after a patient death. In 2006, a 12-week Phase II trial of CJC-1295 DAC for HIV-associated lipodystrophy (192 patients) was stopped after a participant died of a myocardial infarction roughly three hours after a dose. The investigating physician attributed the death to pre-existing coronary artery disease rather than the drug, but the sponsor, ConjuChem, discontinued the program as a precaution. It’s a single case in a specific, medically complex population — not proof of causation — but it’s part of the honest record and rarely mentioned in peptide-vendor marketing.
• The evidence base has not meaningfully grown since. As of 2026, CJC-1295 has no FDA-approved indication, no completed Phase III program, and no active registered trials for the uses most commonly discussed online.

Current regulatory status

CJC-1295 is not an FDA-approved drug. Unlike BPC-157, TB-500, KPV, and MOTS-c, it was not part of the July 2026 PCAC review. It was reviewed earlier: on December 4, 2024 the PCAC voted 0-13 against adding CJC-1295 to the 503A Bulks List, agreeing with FDA, and its salt forms were also rejected. It is therefore not eligible for pharmacy compounding, and nothing in the 2026 reclassification changed that. For the current status of CJC-1295 alongside other peptides, see the live legal status tracker.

What people discuss with providers

Conversations with licensed providers about CJC-1295 typically focus on the gap between the pharmacological effect (a temporary GH/IGF-1 rise) and the outcomes it’s marketed for, the 2006 safety signal and what it does and doesn’t tell us about cardiac risk, and — since it isn’t currently 503A-eligible — what that means for legal access. This is general education, not a recommendation, and isn’t a substitute for an individualized medical evaluation.

Sources

• Teichman et al. — “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults,” J Clin Endocrinol Metab 91(3):799–805, 2006
• aidsmap — “Lipodystrophy study halted after patient death”
• FDA — 503A Bulk Drug Substances Nominations, CJC-1295 docket materials

This article is educational and is not medical advice. Talk to a licensed provider before making any health decision.

← All articles